MAB80124
Anti-Human Metapneumovirus Antibody, clone 132
clone 132, Chemicon®, from mouse
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
hMPV
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
132, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
flow cytometry: suitable
immunofluorescence: suitable
isotype
IgG2a
shipped in
wet ice
Related Categories
General description
Human metapneumovirus (hMPV) is a member of the pneumovirinae subfamily of paramyxoviruses, first described in 2001 from pediatric respiratory specimens in the Netherlands. It is an enveloped pleomorphic virus with a single negative-strand RNA genome. Two major serotypes, A and B, have been described. Several studies identified hMPV in specimens worldwide, and estimated that by age 5 years 70% of children have developed antibodies to hMPV.
Application
Anti-Human Metapneumovirus Antibody, clone 132 is an antibody against Human Metapneumovirus for use in ELISA, FC & IF.
Physical form
Format: Purified
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Xiao Xiao et al.
Nature communications, 13(1), 2546-2546 (2022-05-11)
Human metapneumovirus (hMPV) belongs to the Pneumoviridae family and is closely related to respiratory syncytial virus (RSV). The surface fusion (F) glycoprotein mediates viral fusion and is the primary target of neutralizing antibodies against hMPV. Here we report 113 hMPV-F
Aimin Tang et al.
Nature communications, 10(1), 4153-4153 (2019-09-14)
Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation
Charles J Russell et al.
Virology, 509, 60-66 (2017-06-13)
Human metapneumovirus (hMPV) infections pose a serious health risk to young children, particularly in cases of premature birth. No licensed vaccine exists and there is no standard treatment for hMPV infections apart from supportive hospital care. We describe the production
Xiao Xiao et al.
mAbs, 11(8), 1415-1427 (2019-08-14)
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in young children and older adults. Currently, no licensed vaccine is available, and therapeutic options are limited. The primary target of neutralizing antibodies to RSV is the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service